CompletedNot Applicable

Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei

China36 participantsStarted 2025-02-17

Plain-language summary

The main objective of this study is to combine HIPEC regimens with Flura-seq to detect the effects of different HIPEC regimens (cisplatin vs. cisplatin+ docetaxel) on the nascent transcriptome of PMP tumors, so as to quantitatively assess the efficacy of different HIPEC regimens in the early stage, and to lay the foundation for optimizing the HIPEC regimens and exploring new therapeutic targets.

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-75 years old, regardless of gender and race; * Pathologically confirmed as pseudomyxoma peritonei; acceptable for CRS+HIPEC treatment; * KPS score ≥ 60, with expected survival time more than 12 months; * The functions of important organs are basically normal, with no significant abnormalities in liver or kidney function; * No history of allergy to biological products; * No serious bacterial or viral infection; * Non-pregnancy and lactation; * The patient or his/her delegate understands and cooperates with the treatment and signs the informed consent for the treatment. Exclusion Criteria: * Highly allergic or with a history of severe allergies, especially to biological products; * Shock, systemic failure, unstable vital signs, and inability to cooperate with the examination; * Those who have mental or psychological diseases and cannot cooperate with treatment and curative effect evaluation; * T-lymphocyte carcinoma/tumor; * Patients with systemic infection or severe local infection requiring anti-infection treatment; * Complicated with dysfunction of heart, lung, brain, kidney, liver and other important organs; * Coagulation disorders (e.g., hemophilia); * Infectious diseases (e.g. HIV, RPR, active TB, etc.); * Pregnant or lactating women, or women who have pregnancy plans within half a year; * Patients who are taking immunosuppressive drugs or long-term anti-rejection drugs after organ transplantation; * Patients with severe autoimmune diseases…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Changes in RNA in Tumor Tissues Before and After HIPEC

Timeframe: From the initiation of Cytoreductive Surgery (CRS) to the completion of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). CRS takes 4-8 hours, HIPEC takes 1 hour. Pre and post-HIPEC tumor tissues were collected for RNA-sequencing.

Trial details

NCT IDNCT06839378

SponsorBeijing Tsinghua Chang Gung Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08-06

Results submitted2025-11-30

View on ClinicalTrials.gov More Pseudomyxoma Peritonei trials